Current Rheumatology Reports

, Volume 14, Issue 4, pp 303–309

Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?


DOI: 10.1007/s11926-012-0254-6

Cite this article as:
Stohl, W. Curr Rheumatol Rep (2012) 14: 303. doi:10.1007/s11926-012-0254-6


For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment of systemic lupus erythematosus (SLE). This drug, belimumab, is a monoclonal antibody that neutralizes the B-cell survival factor, B-lymphocyte stimulator (BLyS). Although belimumab has demonstrated a very favorable safety profile, many SLE patients have failed to clinically improve from belimumab therapy. Three additional BLyS antagonists (atacicept, blisibimod, tabalumab) are currently undergoing clinical testing. These antagonists subtly differ from belimumab in their biologic targets, and each is administered through a route (subcutaneous) that differs from the route through which belimumab is currently delivered (intravenous). Whether these differences will have meaningful consequences for efficacy and safety remains to be determined.


APRIL Atacicept BCMA Belimumab Blisbimod (A-623) BLyS/BAFF BR3 Systemic lupus erythematosus Tabalumab (LY2127399) TACI SLE 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of RheumatologyUniversity of Southern California Keck School of MedicineLos AngelesUSA

Personalised recommendations